Eli Lilly and Company Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 29, 2026 results vs estimates
Eli Lilly and Company Forecast
Eli Lilly and Company short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 35.9% a year, a typical one-standard-deviation range is 1,304–1,443 over a week, 1,231–1,516 over a month and 880.07–1,867 over a year. (Signals as of 1 Nov 2026.)
Eli Lilly and Company Price Chart
Eli Lilly and Company Factors
YoY −14.0%
YoY −11.4%
YoY −23.9%
YoY −22.4%
YoY −11.3%
YoY +69.1%
YoY +16.3%
YoY −10.9%
YoY +28.9%
YoY +36.9%
YoY −17.7%
YoY −10.2%
YoY −19.4%
YoY +29.7%
YoY −31.2%
YoY 0.0%
YoY +10.8%
Eli Lilly and Company fundamentals: income statement, balance sheet & cash flow
Eli Lilly and Company reported revenue of $65.18bn and net income of $20.64bn in FY2025, the year ended 31 December 2025 — revenue up 44.7% and net income up 94.9% on the prior year. Free cash flow was $8.97bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 65.18 | 45.04 | 34.12 | 28.54 | 28.32 |
| Cost of revenue | 11.05 | 8.42 | 7.08 | 6.63 | 7.31 |
| Gross profit | 54.13 | 36.63 | 27.04 | 21.91 | 21.01 |
| Research & development | 13.34 | 10.99 | 9.31 | 7.19 | 7.03 |
| Selling, general & admin. | 11.09 | 8.59 | 6.94 | — | — |
| Operating income | 29.70 | 17.04 | 10.79 | 7.13 | 6.36 |
| EBITDA | 31.69 | 18.81 | 8.57 | 8.66 | 8.04 |
| Interest expense | 0.80 | 0.78 | 0.49 | 0.33 | 0.34 |
| Pre-tax income | 25.73 | 12.68 | 6.55 | 6.81 | 6.16 |
| Income tax | 5.09 | 2.09 | 1.31 | 0.56 | 0.57 |
| Net income | 20.64 | 10.59 | 5.24 | 6.24 | 5.58 |
Download Eli Lilly and Company fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.LLY.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Eli Lilly and Company
Explore MacroFinance macro & markets research and analysis.
Eli Lilly and Company Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Eli Lilly and Company; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Eli Lilly and Company’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Eli Lilly and Company (United States)
Eli Lilly and Company is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Eli Lilly and Company
Frequently asked questions
What is Eli Lilly and Company?
What is the latest Eli Lilly and Company price?
Is Eli Lilly and Company in an uptrend?
How volatile is Eli Lilly and Company?
What factors affect Eli Lilly and Company?
Which trading strategies trade Eli Lilly and Company?
How are Eli Lilly and Company returns analysed?
Where can I download free Eli Lilly and Company historical data?
Free Eli Lilly and Company historical data (last 10 years)
Browse or instantly download the last 10 years of Eli Lilly and Company daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.LLY.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 1347.11 |
| 2026-11-19 | 1351.12 |
| 2026-11-18 | 1382.75 |
| 2026-11-17 | 1415.55 |
| 2026-11-16 | 1431.67 |
| 2026-11-13 | 1443.5 |
| 2026-11-12 | 1425.55 |
| 2026-11-11 | 1435.55 |
| 2026-11-10 | 1430.55 |
| 2026-11-09 | 1410.24 |
About this stock
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.